<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>EFBA AE Journal</title>
    <link>https://efba.ae/en/blog/</link>
    <atom:link href="https://efba.ae/en/blog/feed.xml" rel="self" type="application/rss+xml"/>
    <description>Evidence-led articles on anti-aging and longevity science, molecular actives and formulation from EFBA</description>
    <language>en-GB</language>
    <copyright>© 2026 EFBA</copyright>
    <lastBuildDate>Thu, 18 Jun 2026 09:00:00 +0000</lastBuildDate>
    <image>
      <url>https://efba.ae/assets/img/blog/nad-vs-nmn-longevity-cover.webp</url>
      <title>EFBA AE Journal</title>
      <link>https://efba.ae/en/blog/</link>
    </image>
    <item>
      <title>NAD+ vs NMN: What the Evidence Actually Says</title>
      <link>https://efba.ae/en/blog/nad-vs-nmn-longevity/</link>
      <guid isPermaLink="true">https://efba.ae/en/blog/nad-vs-nmn-longevity/</guid>
      <pubDate>Thu, 18 Jun 2026 09:00:00 +0000</pubDate>
      <category>Longevity Science</category>
      <description>NMN is a precursor; NAD+ is the coenzyme cells use. How the two differ in biochemistry, absorption and human evidence — an evidence-graded comparison for clinicians, pharmacists and partners.</description>
    </item>
  </channel>
</rss>
